relapsed/refractory Multiple Myeloma

• A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed mult … Pending
  2025-520976-25-00 4
• A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myelom … Pending
  2025-522776-93-00 1
• A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) Pending
  2025-524181-26-00 4
• A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip … Pending
  2025-524876-43-00 5
• A clinical trial for patients with relapsed or refractory multiple myeloma, using an experimental drug called ISB 2001 for the first time in … Recruiting
  2023-507071-21-01 1 2025-08-14
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27
• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple M … Recruiting
  2023-506247-42-00 3 2022-08-17
• A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse … Recruitment ended
  2023-508426-10-00 3 2024-06-03
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Recruitment ended
  2023-503444-13-00 5 2023-03-29
• A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMB … Recruitment ended
  2024-516147-32-00 9 2022-12-06
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refract … Recruitment ended
  2023-505212-38-00 3 2022-11-16
• A Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multi … Recruitment ended
  2023-505865-94-00 9 2022-10-26
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti- … Recruitment ended
  2023-506871-88-00 3 2022-10-07
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Recruitment ended
  2023-503441-55-00 4 2021-10-14
• A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function Recruitment ended
  2023-506063-34-00 3 2021-07-23
• A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Recruitment ended
  2023-503440-14-00 3 2021-03-08
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex … Recruitment ended
  2023-506877-37-00 5 2020-09-28
• A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl … Recruitment ended
  2023-508962-14-00 5 2020-06-18
• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Recruitment ended
  2023-503438-40-00 7 2017-10-05
• A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma Ended
  2024-513439-25-00 1 2025-04-30
• A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cell … Ended
  2022-500782-27-00 7 2023-11-14
• A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refr … Ended
  2022-502057-33-00 7 2023-10-02
• To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo … Ended
  2024-510644-31-00 3 2022-06-10

Showing 1–23 of 23 trials